Compare Incyte Corporation (INCY) vs VICI Properties Inc (VICI) Price & Performance

Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.

Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.

VICI Properties trades at $22.64, down 0.4% on the day, with a bearish technical outlook despite strong fundamentals. The REIT maintains exceptional profitability with 67.5% net margins and trades at attractive valuations (P/E 8.83, P/B 0.86). Recent earnings show mixed results with Q1 2026 beating expectations but Q2 2026 missing, while the company continues expanding its tenant base through new lease agreements.

Wall Street remains bullish with 75% buy ratings and a $28.90 consensus target, representing 28% upside. Key risks include tenant concentration and rising interest rates, but the 7.8% dividend yield appears well-covered by strong cash flows. The current discount to NAV presents a compelling opportunity for income-focused investors.